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KEY POINTS
 Peptide receptor radionuclide therapy (PRRT) with either 90Y-octreotide or 177Lu-octreotate is an
efficient and relatively safe treatment of unresectable or metastatic neuroendocrine tumors.
 Over 2 decades, PRRT has been demonstrated to provide effective tumor response, symptom
relief, and quality-of-life improvement, biomarker reduction, and, ultimately, a positive impact on
survival.
 PRRT is generally well tolerated. Chronic and permanent effects on target organs, particularly the
kidneys and the bone marrow, are generally mild if appropriate precautions are undertaken.INTRODUCTION
Neuroendocrine neoplasms are variously referred
to as “carcinoids,” neuroendocrine tumors
(NETs), or gastroenteropancreatic (GEP) neuroen-
docrine (NE) neoplasms (GEP-NENs).1 Most NETs
are located in the gastroenteropancreatic tract
and in the lung (Fig. 1).1 In general, they are
slow-growing tumors but in some instances may
behave in a highly aggressive fashion (neuroendo-
crine carcinoma; NEC).2 Due to their diverse and
protean symptoms (sweating, flushing, diarrhea,
bronchospasm, and anxiety), diagnosis is oftenThe authors have nothing to disclose.
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only identified when metastatic spread has
occurred. Metastasis can occur locally, in the
mesentery, in adjacent lymph nodes, and by he-
matogenous spread. In most, the liver is the domi-
nant site of metastatic spread, but lung, bone, and
brain may also be affected.3 As a consequence of
the substantial percentage of individuals with met-
astatic disease, most therapeutic strategies are
directed at the management of hepatic second-
aries or local recurrence.4
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Fig. 1. Incidence of different types of NETs. Most are located in the gastroenteropancreatic tract and the lung.
Bodei et al2treatment of NETs is typically multidisciplinary and
is individualized according to the tumor type,
extent of the disease, and level of symptoms.
GEP-NENs were previously considered rare, but
in fact, not only are increasing in incidence (3.65/
100,000), but also occur as frequently as testicular
tumors, Hodgkin disease, gliomas, and multiple
myeloma.1 They represent a significant clinical
issue for 2 reasons. First, at diagnosis, 40% to
95% are metastatic (depending on the primary
site) and, second, there is a paucity of evidence-
based best practice strategies.1 A key manage-
ment issue is that at diagnosis, 65% to 95% of
GEP-NENs (excluding appendiceal and gastric
NETs) have metastasized to the liver.5,6 Therapeu-
tic endeavors are therefore in most instances
focused on the management of metastatic dis-
ease, and neuroendocrine liver metastases (NE
LMs) represent one of the most significant prog-
nostic factors irrespective of the primary tumor
site. Thus, the 5-year survival in historical series
is 13% to 54% compared with 75% to 99% in in-
dividuals without hepatic metastases.7,8
Recent experience from some specialized cen-
ters documents improved 5-year overall survival
rates of 56% to 83% for metastasized intestinal
NENs and 40% to 60% for pancreatic NENs.9
Although these data have been used to suggest
that NET management should only be undertaken
at specialized centers, such proposals may not be
realistic in the current medical economic climate.Despite the use of a diverse variety of complex
management strategies for NE LMs, surgery re-
mains the only treatment option with the potential
to cure.9 For unresectable tumors, optimal selec-
tion of palliative treatment options (timing and mo-
dality) is of paramount importance to maintain or
improve quality of life (QoL) and prolong overall
survival.OVERVIEW
Unlike many well-studied neoplastic diseases
such as breast or colon cancer, NETs represent
relatively recent clinicopathologic entities. As a
consequence, their management has evolved
over the last decade based on increased under-
standing of their tumor biology and molecular
regulation. Given the diverse appreciation of the
disease complexity, a variety of different se-
quences of diagnostic and therapeutic procedures
has being proposed and debated in individual
medical centers.10 Key issues involved in the
development of an optimal management strategy
include the precise type of the tumor, the grade
and stage of the lesion, and the overall patient’s
general condition. Ideally, removal of the primary
tumor should be initially undertaken and, there-
after, appropriate strategies should be developed
for the management of residual disease. It is the
latter issue that often evokes controversial discus-
sion because there exists a paucity of rigorous
PRRT for Advanced Neuroendocrine Tumors 3prospective randomized trials to support a clearly
defined therapeutic strategy. In most cases, there-
fore, the therapeutic strategy is usually determined
by discussion based on experience and institu-
tional bias.10 Although a variety of management
guidelines have been developed, they tend to
vary from country to country. The most significant
limitation of the published recommendations is
that, in most circumstances, they are based on
low-grade evidence obtained from retrospective
studies of heterogeneous patient and tumor
populations.4
In principle, however, the choice of therapy de-
pends on the primary therapeutic aim for a partic-
ular individual, which may range from an attempt
at complete surgical eradication of the disease to
amelioration of symptoms. In most circumstances,
complete removal of disease is impossible
because of a late clinical presentation with evi-
dence of metastatic progression (Fig. 2). The latter
may be local or more commonly involves hepatic
metastasis and occasionally spread to bone,
lungs, and even brain. Thus, for practical clinical
purposes, most therapy is deployed toward
decreasing the size of metastatic lesions, reducing
metastatic growth, and ameliorating symptoms (in
functional lesions).11 To achieve these goals, aFig. 2. Treatment options in bronchopulmonary NETs, inc
agement of metastatic or unresectable disease comprises
including PRRT.wide variety of therapeutic strategies have been
developed. The surgical options include resection
of the primary, hepatic metastases resection,
radiofrequency ablation, and even hepatic trans-
plantation.12 Interventional radiology techniques
include embolization of hepatic metastases (with
or without cytotoxic agents) or the use of radioac-
tive microspheres. Medical therapy ranges from
the use of bioactive agents such as somatostatin
analogues or interferon to standard chemo-
therapy. More recently, a variety of novel mole-
cular targeted agents, including Everolimus,
Sunitinib, and Bevacuzimab, have been used
with marginal efficacy.13 Of particular interest has
been the development of targeted radiotherapy
using a variety of different isotopes, including in-
dium, yttrium, and lutetium.14 This novel therapeu-
tic strategy, delivered by intravenous infusion, has
been designated peptide receptor radionuclide
therapy (PRRT) (Fig. 3).NON-SOMATOSTATIN-BASED THERAPIES
Medical Therapy
In general, the type of therapy used depends on
the grade and proliferation of the tumor. High-
grade, rapidly proliferating lesions, especiallyluding both typical and atypical carcinoids. The man-
locoregional strategies as well as systemic treatments,
Fig. 3. Treatment outcomes for NETs.
Therapy-related survival is the highest
in resectable tumors. At diagnosis,
40% to 95% of tumors have already
metastasized (depending on location
of the primary lesion). PRRT compares
well with other techniques, including
locoregional approaches and chemo-
therapy. Toxicity is a major adverse
event in the latter category of
therapy.
Bodei et al4from the pancreas (NEC G3), are amenable to
chemotherapy, whereas “targeted” therapies (eg,
Everolimus or Sunitinib) and biotherapy (eg, so-
matostatin analogues or interferon) are used in
“slower” growing lesions (NET G1 or G2). Chemo-
therapy has greater objective response rates
(35%–40%) in pancreatic NETs than Everolimus
or Sunitinib.15 The molecular markers that identify
patients who would optimally benefit from individ-
ual or combinations of therapies, apart from so-
matostatin receptor expression, are currently
unknown. For chemotherapy (including 5-fluoro-
uracil, doxorubicin, and streptozotocin), the
volume of LM is the most significant predictor
of outcome and directly correlates with
progression-free survival (PFS). Potential prob-
lems with chemotherapy include cumulative risks
of nephrotoxicity/myelosuppression and systemic
adverse events.16 For targeted therapies, there is
evidence to suggest a specific use in NE LMs. In
the Everolimus study in pancreatic NETs, 92% of
whom had NE LMs, the agent was associated
with improved PFS (6.4 months compared with
placebo), an effect that was long lasting (35% sta-
ble at 18 months). Tumor remissions were, how-
ever, rare (5%). In the Sunitinib study (95% of
pancreatic NETs had distant metastases including
NE LMs), a significant PFS prolongation
(5.9 months compared with placebo) was
achieved with tumor remissions of less than
10%. There is no evidence for use of Sunitinib or
Everolimus in LM of intestinal origin. For bio-
therapies, there is a modest amount of data for
interferon, but for somatostatin analogues, the
Placebo controlled, double-blind, prospective,
Randomized study on the effect of Octreotide
LAR in the control of tumor growth in patients
with metastatic neuroendocrine MIDgut tumors
(PROMID) study on small bowel NETs suggestedthat any benefit from these agents was defined
by the extent of liver involvement. Thus, individuals
with less than 10% involvement had better PFS
than those with greater than 10% involvement. In
summary, 3 prospective randomized trials provide
only marginal evidence for the efficacy of these
agents (Everolimus and Sunitinib) in the treatment
of NE LMs.Angiographic Liver-directed Techniques
Liver-directed intra-arterial therapies available in
the treatment of unresectable NE LMs include
trans-arterial embolization (TAE), transarterial che-
moembolization (TACE), and selective internal
radiotherapy (SIRT) with Yttrium-90 (90Y) micro-
spheres. For TAE or TACE, symptomatic re-
sponses have been reported in 53% to 100% of
patients (10–55 months) and morphologic re-
sponses were noted in 35% to 74% (6–63 months)
with a PFS ofw18 months with 5-year survivals of
40% to 83%. Mortality and morbidity, including
postembolization syndrome, varied between 0%
to 5.6% and 28% to 90%, respectively; TAE ap-
pears to be superior to TACE for small bowel
NETs. In a recent multicenter report on SIRT, sta-
ble disease by imaging was achieved in 22.7%, a
partial response in 60.5%, and complete response
in 2.7%. A median survival of 70 months was re-
ported with progressive disease evident in 4.9%.
The most frequently observed clinical toxicities
were fatigue and nausea (occurring in <10%). In
an international multicenter prospective treatment
registry to investigate the safety and efficacy of he-
patic artery therapy for primary or secondary liver
tumors, response rates for SIRT and TACE were
comparable at 6 months in a group of 43 patients
with comparable NE LM disease. At 12 months,
however, a significantly lower response rate was
PRRT for Advanced Neuroendocrine Tumors 5observed in the SIRT group: 46% versus 66%.
Although SIRT may have advantages over TAE/
TACE in terms of reduced adverse effects and
the requirement for fewer treatments, it can be
associated with side effects in terms of radiation
gastritis, duodenal ulceration, and sclerotic alter-
ation of healthy liver parenchyma. SIRT is also
relatively expensive and patients require careful
selection because lung shunting may be an issue.
It is clear that more long-term outcome data are
required to assess the efficacy of SIRT.
SOMATOSTATIN ANALOGUE-RELATED
THERAPIES
“Cold,” non-radiolabeled, somatostatin analogues
exhibit significant effects in terms of ameliorating
symptoms. The various synthetic peptide ana-
logues each have different binding properties to
the 5 somatostatin receptor subtypes. Generally,
however, they represent an effective class of
agents that inhibit peptide secretion from NET
cells with relatively few and limited adverse
events.17 This is particularly evident in small bowel
NETs, which often exhibit severe flushing and diar-
rhea. Similar positive effects are evident in func-
tional pancreatic NETs, such as glucagonoma
and VIPoma. Unfortunately, administration re-
quires monthly injections, which are inconvenient
and often painful. Furthermore, the beneficial
pharmacologic effects are not always sustained
(breakthrough) because of either tachyphylaxis or
increasing production of bioactive products by
an advancing tumor.18 It has been proposed thatFig. 4. Mechanism of effectiveness of PRRT. After the som
the membrane somatostatin receptor, the radiopeptide/
radioactivity is transported into the intracellular receptor
its action in proximity to the nucleus.cold somatostatin analogues decrease prolifera-
tive activity of NETs. The evidence for this asser-
tion is, however, neither rigorous nor robust and,
if such an effect is present, it is only evident in a
small minority of lesions.19,20
PRRT with radiolabeled somatostatin analogues
is an innovative treatment of inoperable or metas-
tasized, well/moderately differentiated, NETs,
particularly of the GEP (and of the lung).21 Somato-
statin analogues represent, to date, the prototype
and the most successful paradigm of radiopeptide
therapy. This successful paradigm of radiopeptide
therapy reflects the development of a synthetic
peptide analogue, octreotide, and its variants, us-
ing the native somatostatin molecule as a base.
Overall, the therapeutic efficacy of somatostatin
analogues and, subsequently, of their radiolabeled
counterparts, is due to their high affinity for so-
matostatin receptors subtype 2 (S2) and moderate
affinity for subtype 5 (S5) and is consistent with the
prevalent overexpression of S2 and S5 in most
NETs.22
PRRT Background
The rational scientific PRRT basis relies in the
presence of a somatostatin receptor on the sur-
face of NETs to which an isotopically labeled ra-
diopeptide is directed. The subsequent cellular
radiopeptide internalization thereafter delivers
the radioactivity directly into the intracellular
compartment of the tumor (Fig. 4). The clinical
process of PRRT consists in the systemic admin-
istration of a suitably radiolabeled syntheticatostatin (SS) analogue linked to the isotope binds to
somatostatin receptor complex is internalized. Thus,
recycling compartment of the NET cell, where it exerts
Fig. 5. Objective response to 177Lu-octreotate PRRT in
an unresectable rectal NETwith hepatic metastasis (A)
basal 177Lu-octreotate scan (solid arrow). The patient
underwent a prior rectosigmoid resection and ex-
hibited disease progression following chemotherapy
with capecitabine. (B) The final 177Lu-octreotate scan
after 8.6 GBq of 177Lu-octreotate. Evidence of a partial
objective response (dashed arrow) enabled subse-
quent embolization followed by a multidisciplinary
treatment sequence plan.
Bodei et al6somatostatin analogue, fractionated in sequential
cycles (usually 4–5) every 6 to 9 weeks, until the
intended total amount of radioactivity has been
delivered. The precise amount administered de-
pends mainly on the limitations imposed by renal
irradiation and to a lesser extent on bone
marrow.
PRRT was introduced into clinical practice in
1994. It represented a logical step following the
initial development of the diagnostic technique
for in vivo localization of NETs using the radiola-
beled somatostatin analogue [111In-DTPA0-D-
Phe1]-octreotide or 111In-pentetreotide.23 Thus,
the same principle was used, but increased
isotope activity (high-dose 111In-pentetreotide)
provided a therapeutic as opposed to a diagnostic
benefit. Therapeutic efficacy reflects the activity of
the Auger and conversion electrons emitted by
111In. Despite the theoretical considerations, par-
tial remissions remained rare.24 As a consequence
of these relatively disappointing results, isotopes
with higher energy and longer range, such as the
pure b emitter 90Y, were considered more appro-
priate for therapeutic evaluation. The b particles
emitted by 90Y (maximum energy 2.27 MeV, pene-
tration range Rbmax 11 mm, half-life T1/2 64 hours)
are advantageous, allowing simultaneously a
direct killing of somatostatin receptor-positive
cells and a cross-fire effect that targets nearby
receptor-negative tumor cells. To facilitate efficacy
further, novel octreotide analogues were devel-
oped. Thus, for 90Y, a new analogue, Tyr3-octreo-
tide, with a similar pattern of affinity for
somatostatin receptors, was developed at the Uni-
versity of Basel. This analogue was characterized
by high hydrophobicity, ease of labeling with
111In and 90Y, and tight binding to the bifunctional
chelator DOTA, which securely encloses the radio-
isotope (1,4,7,10-tetra-azacyclododecane-
N,N0,N0 0,N0 0 0-tetra-acetic acid).25,26
[90Y-DOTA0,Tyr3]-octreotide or 90Y-DOTATOC
or 90Y-octreotide was initially used in the treatment
of metastatic NETs in 1996. The excellent symp-
tomatic and objective response following several
cycles of 90Y-octreotide therapy encouraged
further studies to examine the potential of PRRT
in NET disease.27 As a consequence of the posi-
tive experience with 90Y-octreotide, it became
the most used radiopeptide in the first decade of
PRRT experience.14,28–31
Since 2000, however, a more effective
analogue, octreotate (Tyr3, Thr8-octreotide), with
6-fold to 9-fold higher affinity for somatostatin
S2 has been used. The chelated analogue
[DOTA]0-Tyr3-octreotate or DOTATATE can be
labeled with the b-g emitter Lutetium-177 (Ebmax
0.49 MeV, Rbmax 2 mm, T1/2 6.7 days) and hasbeen investigated in several clinical phase I and
II studies (Fig. 5).14,32–34 177Lu-octreotate has sub-
sequently become one of the most frequently
used radiopeptides for PRRT; this has been
particularly evident in recent years given its effi-
cacy, tolerability, and manageability. 177Lu-oc-
treotate is currently being evaluated in a
randomized phase III registration trial in small
bowel NETs.
PRRT Clinical Protocol
Candidates for PRRT with radiolabeled somato-
statin analogues are individuals with tumors that
exhibit a significant somatostatin receptor overex-
pression. A key issue in the inclusion criteria is that
the somatostatin receptors should be functional,
namely, be able to internalize the receptor-
analogue complex and retain the radioactivity in-
side the cell. Thus, the critical issues for effective
therapy remain the somatostatin receptor overex-
pression and the evidence of functionality.
To be considered appropriate candidates for
therapy, individuals should be selected based on
scintigraphy with 111In-pentetreotide (or, more
recently, receptor positron emission tomography
[PET] with 68Gallium-labeled octreotide). Such im-
ages should indicate an adequate uptake (at least
equal to the uptake of normal liver) as evidence of
adequate expression of targetable somatostatin
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late an appropriate high tumor dose with low expo-
sure to normal tissues that express physiologic
levels of somatostatin receptors.35
Scintigraphic or PET tomoscintigraphic evalua-
tion is to date the most accurate noninvasive
method to identify and confirm the overexpression
of functioning receptors. An alternative strategy is
to use immunohistochemistry, which provides
similar information at the time of biopsy. Immuno-
histochemistry, however, is not as quantitatively
accurate as molecular analysis (polymerase chain
reaction and Western blot), which can precisely
define the level of somatostatin receptors and their
functionality.36 Optimally, the use of in vivo func-
tional scintigraphic or PET methods facilitates
the simultaneous evaluation of the receptor den-
sity and the internalization capacity in real-time in
all lesions.
When evaluating a receptor scan to determine
PRRT selection, it is important to exclude false
positives. For the most part, these represent accu-
mulations of inflammatory cells, which express
somatostatin receptors. False positives include
gallbladder (inflammation), accessory spleens,
recent surgical scars (inflammatory infiltrate),
previous radiotherapy, and any other cause of
granulomatous-lymphoid infiltrate that can mimic
the presence of NET tissue.
Potential causes of false negatives should also
be considered. These false negatives are mainly
represented by small, subcentimeter lesions, un-
der the resolution limit of the instrument (although
this limitation is partially overcome by receptor
PET/computed tomography). In addition, certain
tumors, especially benign insulinomas and most
highly malignant NETs, do not express adequate
somatostatin receptors for detection.PRRT Technique
PRRT consists of the cyclical systemic administra-
tion of the radiopeptide. The cumulative activity,
fractionated in multiple cycles, is able to irradiate
the tumor efficiently, without surpassing the con-
ventional 25- to 27-Gy absorbed dose threshold
to the kidneys, which are the dose-limiting organs.
Recently, it has been reported that the biologic
effective dose (BED) as opposed to the absorbed
dose provides a dose threshold value that is
slightly higher.37 The rhythm of fractionation, every
6 to 9 weeks, is based on the time that has been
determined as necessary to recover from possible
hematological toxicity.
To diminish the renal dose of irradiation, patients
are premedicated with an intravenous infusion of
positively charged amino acids (lysine or arginine)in the amount of at least 25 g per day. This infusion
is started 2 to 3 hours before the isotope adminis-
tration and is maintained until 2 to 3 hours
following cessation of the isotope infusion. The
infusion has the objective of simultaneously hy-
drating the patients and reducing the renal radio-
activity dose by providing competitive inhibition
of the proximal tubular reabsorption of the radio-
peptide. The radiopeptide is intravenously admin-
istered slowly over 20 minutes in approximately
100 mL of saline. In some circumstances, mild
adverse events are experienced during the infu-
sion. These mild adverse events include gastroin-
testinal symptoms, such as a slight nausea, and
occasionally, emesis. These symptoms may be re-
lated to the amino acid coadministration, but are
easily controlled with appropriate medication.21
PRRT Efficacy
In almost 2 decades of clinical application, PRRT
with 90Y-octreotide or 177Lu-octreotate has pro-
vided effective clinical therapy as indicated by tu-
mor responses, symptom relief, and QoL
improvement as well as a decrease in biomarker
levels and enhanced survival (see Fig. 5). Several
clinical phase I–II trials indicate that radiolabeled
somatostatin analogue PRRT is among the prom-
ising newly developed targeted tools in NETs, with
registered objective responses in more than 30%
of individuals, mainly of GEP origin.14,31,33,35,38–40
PRRT and Bronchopulmonary NETs
Although bronchial NETs overall represent the
second most common type of NET among differ-
entiated histologic types, there have been few,
dedicated PRRT trials. The PRRT data for bron-
chopulmonary NETs are therefore typically extrap-
olated from more general studies (Fig. 6).
In the first decade of experience, 90Y-octreotide
was the most commonly used radiopeptide. How-
ever, all the published results derive from different
phase I–II studies performed independently by a
variety of centers. As a consequence, information
is heterogeneous as to inclusion criteria and spe-
cific treatment schemes. A rigorous direct com-
parison is therefore virtually impossible at this
time. Nevertheless, despite these limitations,
objective responses have been documented in
10% to 34% of patients (Table 1).14,29,30,39–42
Current isotope administration protocols
schedule the injection of standard radioactivities
that were established based on previous dose
escalation studies as well as clinical experience.
This practice has resulted in substantial differ-
ences among protocols, as to activities, which
may be fixed or related to body weight or surface,
Fig. 6. Role of diagnostic and therapeutic tools in the management of bronchopulmonary NETs ranging from sur-
gical resection to PRRT.
Bodei et al8number of cycles, and time intervals between
cycles.
The initial studies with 90Y-octreotide were un-
dertaken in individuals with very advanced dis-
ease. However, the documented effectiveness of
the therapy, even in these situations, led to the us-
age of PRRT in earlier phases of disease because
it was evident that with decreased tumor burden
radiopeptides exhibited a greater efficacy. The
rationale for this strategy was provided by
numerous factors including tumor volume and
the biologic features of the neoplasm. Thus,
more advanced (aggressive) tumors expressed
less somatostatin receptors, increased genetic
mutations, such as in p53,43 and are thus lessTable 1
Clinical results of PRRTwith either 90Y-octreotide or
Ligand (Ref.) Patient Number CRD P
90Y-octreotide41 23 13
90Y-octreotide57 37 27
90Y-octreotide45 36 34
90Y-octreotide28 21 29
90Y-octreotide42 58 9
90Y-octreotide30 90 4
90Y-octreotide40 53 23
90Y-octreotate39 58 23
177Lu-octreotate33 310 29
177Lu-octreotate34 42 31
177Lu-octreotate52 52 39responsive to treatment. Key issues in predicting
optimal PRRT outcome were tumor load, espe-
cially in the liver, and performance status. Evalua-
tion of such indices of prognosis and outcome
concluded that treatment in a phase of “early” pro-
gression rather than a “wait-and-see” approach
was advantageous. Overall, it was apparent that
PRRT treatment in advanced stage disease was
substantially less effective. A further consideration
was the type of disease being treated. Thus, me-
tastases of pancreatic NETs were frequently
more amenable to therapy compared with other
types of NETs. NETs that were active secretors
of bioactive agents (functional) also tended to
relapse very rapidly.44177Lu-octreotate in GEP-NETs
R (%) Response Criteria Outcome (mo)
WHO Not assessed
WHO TTP >26
WHO Not assessed
WHO TTP 10
SWOG TTP 29
SWOG PFS 16
WHO PFS 29
WHO PFS 17
SWOG PFS 33
RECIST TTP 36
SWOG PFS 29
PRRT for Advanced Neuroendocrine Tumors 9In a study carried out at Basel University, 39 pa-
tients with NETs, mostly of GEP origin, were
treated with 4 cycles of 90Y-octreotide, with a cu-
mulative activity of 7.4 GBq. Objective responses,
according to World Health Organization (WHO)
criteria, were described in 23%, with a complete
remission in 2 patients, a partial response in 7 pa-
tients, and a disease stabilization in 27 patients.
Pancreatic NETs (13 patients) showed a better
objective response (38% partial 1 complete)
than other tumor types. A significant related-
symptoms amelioration occurred in most patients.
In this series, 3 patients with progressive bronchial
tumors were also included. All demonstrated dis-
ease stabilization after PRRT.45
In a multicenter phase I study, carried out in Rot-
terdam, Louvain, and Tampa, 60 patients with
GEP-NETs were treated with 4 cycles of 0.9, 1.8,
2.8, 3.7, 4.6, and 5.5 GBq/m2 of 90Y-octreotide
administered at 6 to 9 weekly intervals. In an initial
evaluation of the results (2002) in 32 evaluable pa-
tients, objective responses (according to South-
west Oncology Group [SWOG] criteria) were
evident. These responses constitutedw9% partial
responses and 9%minor responses.46 In a subse-
quent reanalysis of 58 assessable patients of the
same population who were treated with cumula-
tive activities of 1.7 to 32.8 GBq, a 57% clinical
benefit, including stabilization and minor re-
sponses (SWOG criteria), was observed. Objective
responses were described in 5%. The most rele-
vant finding of the study was the observed overall
survival, with a median value of about 37 months
and a median PFS of about 29 months. These re-
sults compared well with the 12-month overall
survival of a historical group treated with 111In-
pentetreotide. The median PFS in this group was
29 months. Characteristically, patients stable at
baseline had a better overall survival than those
who were progressive at baseline. The extent of
disease at baseline was also a predictive factor
for survival.42
The results of 2 phase I–II studies and a retro-
spective evaluation in 141 patients were published
by the Milan group in 2004. Somatostatin
receptor-positive tumors, mainly gastroentero-
pancreatic and bronchial NETs, were treated with
a cumulative activity of 7.4 to 26.4 GBq of 90Y-oc-
treotide, divided into 2 to 16 cycles, administered
4 to 6 weeks apart. The objective response rate
was 26%, including partial and complete re-
sponses (SWOG criteria). Disease stabilization
was observed in 55% and disease progression in
18%. The mean duration of response ranged
from 2 to 59 months (median 18). Most who re-
sponded had GEP-NETs. A significant observation
was that assessment of the objective responseaccording to the basal status indicated that indi-
viduals stable at baseline demonstrated a better
outcome (partial and complete responses in
32%) than individuals with progressive disease
(partial and complete responses in 24%). In this
series, 11 patients with bronchial tumors were
included. Ninety-one percent were in progression
at enrollment and were treated with standard
courses of PRRT, with cumulative activities
ranging from 8 to 22.5 GBq. After completion of
the treatment, 1 patient had a partial remission
and 8 patients showed stabilization of disease
(SWOG criteria). In an earlier escalation study pub-
lished by the same group in patients with
somatostatin-positive tumors (mainly in progres-
sion), 3 patients with bronchial NETs were
included, with resulting stability and partial remis-
sion in 2 patients.28,29
A multicenter study published by Bushnell and
colleagues30 in 2010 evaluated the role of 90Y-oc-
treotide in 90 patients with symptomatic, metasta-
tic “carcinoids” (small bowel NETs). The data
indicated stabilization of tumor response (SWOG
criteria) in 74% as well as a durable amelioration
of symptoms related to the tumor mass and the
hypersecretion of bioactive amines. This trial re-
ported a PFS of 16 months and an overall survival
of 27 months.
More recently, the Basel group published the re-
sults of an open-label phase II trial in 1109 patients
treated with 90Y-octreotide, divided into multiple
cycles of 3.7 GBq/m2 each. Objective morpho-
logic responses (Response Evaluation Criteria In
Solid Tumors [RECIST] criteria) were observed in
378 (34.1%), biochemical responses in 172
(15.5%), and symptomatic responses in 329
(29.7%). In this series, the NET groups were 265
small bowel, 84 bronchial, and 342 pancreatic tu-
mors. The rates of objective response were
26.8%, 28.6%, and 47%, respectively. A longer
survival was correlated with tumor and symptom-
atic response. The best predictor of survival, how-
ever, was the tumor uptake at baseline.31
Protocols combining 177Lu-peptides and 90Y-pep-
tides have been recently considered to take
advantage of the different physical properties of
both 2 radionuclides. In theory, the combination
of the 2 radioisotopes would allow simultaneous
treatment of both larger lesions (based on the
higher energy and penetration range of the parti-
cles emitted by 90Y) and small lesions (based on
the lower energy and penetration range of 177Lu).
This strategy, however, must still be validated in
clinical practice in larger series. Furthermore, the
previously published studies include treatment
schemes wherein 177Lu and 90Y were administered
using empirically designed protocols rather than
Bodei et al10being based on individualized dosimetric ana-
lyses.47,48 The results of PRRT performed in a
Danish cohort of 69 patients treated in Basel with
different combinations of Y-peptides and/or Lu-
peptides were recently published. Complete
response was evident in 5 cases (7.4%), a partial
remission in 11 cases (16.2%), and stability in 42
cases (61.8%). The median PFS was 29 months.
Pancreatic NETs responded better than those
with small bowel tumors. Six patients with bron-
chial NETs were included: one exhibited a partial
remission and 3 were stable.40 Experience has
also been obtained from studies with 90Y-DOTA-
TATE. A group of 60 patients with histologically
proven GEP-NETs were treated with 4.1 to 16.2
GBq per patient (mean 3.7 GBq per therapy) in 1
to 3 cycles. Six months after PRRT completion, a
partial response was evident in 13 patients
(23%), whereas the remaining had stable disease
(77%). The median PFS was 17 months and the
median overall survival was 22 months. Hemato-
logical toxicity WHO grades 3 and 4 were noted
during therapy in 10%, which persisted in 5%. Af-
ter 24 months of follow-up, renal toxicity grade 2
was seen in 7 (11.6%) and the authors emphasized
the need for careful renal monitoring.39 The novel
radiopeptide DOTATATE labeled with 177Lutetium,
177Lu-DOTATATE, or 177Lu-octreotate attained
great popularity since its introduction in clinical
trials in 2000, reflecting its higher affinity for so-
matostatin S2, its easier manageability, a lower
dosimetric burden on the kidney, and the possibil-
ity of obtaining scintigraphic images and dosi-
metric studies at the same time, owing to the g
photon coemission of 177Lu. It is currently there-
fore the most commonly used radiopeptide for
PRRT. The initial clinical trials were undertaken at
Rotterdam University. In a preliminary report, 35
patients with GEP-NETs were treated with 3.7,
5.6, or 7.4 GBq of 177Lu-octreotate, up to a final
cumulative dose of 22.2 to 29.6 GBq, with com-
plete and partial responses in 38% (WHO criteria).
No serious side effects were observed.49 In a sub-
sequent amplification of this series, 131 patients
with somatostatin receptor–positive GEP-NETs
were treated with cumulative activities of 177Lu-
octreotate ranging from 22.2 to 29.6 GBq. In the
125 evaluated patients (SWOG criteria), a com-
plete remission was observed in 3 patients (2%),
a partial remission in 32 patients (26%), minor re-
sponses in 24 patients (19%), and stable disease
in 44 patients (35%). Twenty-two patients (18%)
progressed. Better responses were more frequent
in individuals with a high uptake on baseline 111In-
pentetreotide scintigraphy and those with limited
liver involvement. Conversely, progression was
significantly more frequent with a low performancescore and extensive disease at enrollment. Median
time to progression was greater than 36 months,
comparing favorably to chemotherapy.44 In addi-
tion, 177Lu-octreotate treatment of metastatic
GEP-NETs was also associated with a significant
improvement in the global health/QoL on various
symptom scales, particularly fatigue, insomnia,
pain, as well as role, emotional, and social func-
tions. The effect was more frequent in individuals
with tumor regression, but, surprisingly, it was
also evident in those with progressive disease.50
Of note was the observation that there was no sig-
nificant decrease in QoL in patients who were
asymptomatic before therapy.51 Recently, an eval-
uation of an enlarged series of 504 patients treated
with 177Lu-octreotate, 310 of which were evalu-
ated for efficacy, confirmed the occurrence of
complete and partial remissions in 2% and 28%,
with minor responses in 16% and stability in
35%, respectively (SWOG criteria). However, the
most significant information derived from this
study was the impact of PRRT on survival, with a
median overall survival greater than 48 months
and a median PFS of 33 months. A direct compar-
ison with data obtained from similar patients (in
the literature) showed a substantial 40-month to
72-month survival benefit for PRRT-treated indi-
viduals. Although these data are not derived from
robust/rigorous prospective randomized phase III
trials, this substantial survival difference in all
probability reflects a real impact of PRRT as a ther-
apeutic modality. These PRRT data compare
favorably with other treatments, such as chemo-
therapy, from both the cost/benefit and the tolera-
bility point of view.33 A categorization of objective
response once again indicated that pancreatic
NETs tended to respond better than other GEP-
NETs, although functioning tumors (eg, pancreatic
gastrinomas) tended to relapse in a shorter interval
(median time to progression 20 months vs >36 in
the remaining GEP-NETs).44
A cohort of 51 patients with unresectable/meta-
static NETs, mainly of GEP origin, was treated in a
phase I–II study aimed at defining toxicity and effi-
cacy of 177Lu-octreotate. Patients were divided
into 2 groups, receiving escalating activities, from
3.7 to 5.18 GBq and from 5.18 to 7.4 GBq, with
cumulative activities up to 29 GBq, based on
dosimetry. Partial and complete responses were
observed in 15 patients (32.6%). The median
time to progression was 36 months, with an overall
survival of 68% at 36 months. Nonresponders and
patients with extensive tumor involvement had a
lower survival.34 A recent prospective phase II
study included a cohort of 52 patients with
advanced well/moderately differentiated pancre-
atic NETs who were treated with 177Lu-octreotate.
PRRT for Advanced Neuroendocrine Tumors 11According to the absence or presence of risk fac-
tors for renal toxicity, such as hypertension or dia-
betes, patients were divided into 2 groups and
treated with different levels of activity, full dose
(21–28 GBq) compared with a reduced dose (11–
20 GBq), respectively. Both regimens resulted in
antitumor activity. However, PFS was not reached
at the time of the analysis in the cohort treated with
the full-dose regimen, whereas it was 20 months in
those treated with reduced doses, suggesting the
former scheme should be recommended, when-
ever possible.52 A phase II study was performed
in individuals with “poor responding” tumors,
including bronchial and gastric NECs. Patients
were treated with standard 22.2-GBq to 29.6-
GBq activities. Despite the limited numbers stud-
ied, the observed objective response (SWOG
criteria) was comparable to GEP-NETs. The bron-
chopulmonary NETs results were 5 partial re-
sponses, 1 minor response, and 2 stabilizations
in 9 patients. In the gastric tumor group, there
was 1 complete response, 1 minor response,
and 2 stabilizations (5 patients). In thymic tumors,
the series was too small to draw any conclusions.
The authors concluded that, contrary to previous
findings, PRRT was as effective in bronchial and
gastric NETs as in GEP-NETs.53
A recent study using a salvage protocol with
177Lu-octreotate was published by the Rotterdam
group. Patients in progression were enrolled after
an initial response to PRRT with 177Lu-octreotate,
administered using standard cumulative activities
(22.2–29.6 GBq). In this series, 32 patients with
bronchial or GEP-NETs received 2 additional cy-
cles of 177Lu-octreotate, with a cumulative activity
of 15 GBq. A new objective response occurred in 8
patients (2 partial and 6minor responses), whereas
stabilization was identified in another 8. Median
time to progression was 17months. Both response
rate and duration over time appeared lower than
during the primary treatment. Nevertheless, thisTable 2
Long-term toxicity after PRRTwith either 90Y-octreot
Ligand (Ref.) Patient Number Follow-Up (mo
90Y-octreotide57 41 15
90Y-octreotide45 39 6
90Y-octreotide28 40 19
90Y-octreotide42 58 18
90Y-octreotide40 53 17
90Y-octreotide31 1109 23
177Lu-octreotate33 504 19
177Lu-octreotate34 51 29
a Toxicity grade measured on glomerular filtration rate.“salvage therapy” was well tolerated by most pa-
tients and should be considered a valuable option
for this category of patient.54 In more recent times,
in keeping with recent tendencies in oncology,
PRRT experiences have been focused toward
combination therapies. In particular, combinations
of the radiosensitizer chemotherapy agent, cape-
citibine, with 177Lu-octreotate have been under-
taken. An initial study in a small group (n 5 7)
with progressive GEP-NETs reported encouraging
results.55 Patients were treated with 4 cycles of
standard activities of 177Lu-octreotate followed
by capecitabine (1650 mg/m2) for 2 weeks. No
severe toxicity, particularly hand-foot syndrome
or hematological/renal-associated toxicity, was
evident. Objective responses were observed. A
recent phase II study of progressive NETs (n 5 35)
was reported.56 Patients were treated with 4 cycles
of 7.8 GBq of 177Lu-octreotate followed by capeci-
tabine, 1650 mg/m2 (2 weeks). A 24% objective
response with a 70% stable disease and 6% pro-
gression without adjunctive toxicity (RECIST
criteria) was observed.PRRT Safety Profile
After 18 years of experience, it is apparent that,
from the safety perspective, PRRT with either
90Y-peptides or 177Lu-peptides is generally well-
tolerated. Acute side effects are usually mild with
some of them related to the co-administration of
amino acids (including nausea, and rarely,
emesis). Others are related to the radiopeptide,
such as fatigue (common), or the exacerbation of
an endocrine syndrome, which may rarely occur
in the treatment of functional tumors. Chronic
and permanent effects on target organs, particu-
larly the kidneys and the bone marrow, are gener-
ally mild if the necessary precautions, such as
fractionation and attention to specific risk factors,
are undertaken (Table 2).31,35,40,45,57 In thiside or 177Lu-octreotate in GEP-NETs
) Renal Toxicity (Creatinine) MDS Leukemia
0 0 0
3% Grade 2 0 0
10% Grade 1 0 0
3% Grade 4 1 0
0 1 0
9.2% Grade 3/4a 1 1
0.4% Grade 4 3 0
24% Grade 1 0 0
Bodei et al12respect, it is apparent that, using appropriate
dosimetry, it is possible to deliver elevated ab-
sorbed doses to the tumor, with relative sparing
of healthy organs, such as the kidneys and the
bone marrow (Table 3).
Although acute hematological toxicity is usually
mild and transient, permanent and severe bone
marrow toxicity may be a rare event after PRRT,
as bone marrow–absorbed doses are usually
below the threshold of toxicity.58 Delayed renal
toxicity that may occur if the dose threshold is ex-
ceeded is permanent. The kidneys, as a conse-
quence of their marked radiosensitivity, represent
the critical organs, especially for 90Y-peptides
administration. Renal irradiation derives from the
reabsorption of the radiopeptides at the site of
the proximal convoluted tubules, with a subse-
quent accumulation in the renal interstitium, where
the radioactivity exerts its action. Studies with
external radiotherapy indicate a threshold of toler-
ance in the range of 23 to 27 Gy.59 The recently
introduced BED concept appears more accurate
in predicting toxicity and thus represents a more
universal cipher to express radioactive dosage, ir-
respective of the modality of delivery. The use of
this parameter indicates that the renal threshold
for toxicity after PRRT is approximately
40 Gy.60,61 A critical issue in ameliorating renal
toxicity is provided by the strategy of co-infusing
positively charged amino acids, such as lysine or
arginine. These amino acids competitively inhibit
radiopeptide reabsorption with a consequent 9%
to 53% reduction of the renal radioactivity
dosage.62,63 Despite renal protection, a generally
mild loss of renal function occurs, with a median
decline in creatinine clearance of 7.3% per year
for 90Y-octreotide and a median 3.8% per year
for 177Lu-octreotate.64 Nevertheless, instances of
severe, end-stage, renal damage are currently
extremely rare. Previous instances, for the mostTable 3
Mean absorbed doses for 90Y-octreotide and 177Lu-o
Organ
90Y-octreotide
Mean (Gy/GBq) 13-GBq Course
Kidneya 1.1–5.1 15–66
Bone marrow 0.02–0.2 0.3–2.6
Tumor 1.4–42 18–542
Data derived from published studies58 (with examples of stand
In general, absorbed doses to normal organs (eg, kidney or b
tumor-absorbed doses depend on the level of radioactivity con
tivity accumulation in the tumor. Tumor doses themselves are a
particularly the density of somatostatin receptors on the tum
distribution of radioactivity within the lesions.
a Renal doses are calculated based on the use of renal protpart, represent residual events that occurred dur-
ing the early usage of 90Y-peptide PRRT, when
administration used very high activities in the
absence of renal protection.65
In recent times, it has become apparent that a
higher and more persistent decline in creatinine
clearance with the subsequent development of
renal toxicity is more likely to occur in individuals
with pre-existent risk factors for delayed renal
toxicity. These risk factors include long-
standing and/or poorly controlled diabetes and
hypertension. PRRT with 90Y-peptides in partic-
ular seems more frequently associated with a
reduction of renal function; presumably, this re-
flects the physical characteristics of the radioiso-
tope. In a long-term evaluation of renal toxicity
after PRRT in a group of 28 patients undergoing
PRRT with dosimetric analysis, 23 of whom
were treated with 90Y-octreotide, a low, 28-Gy
BED threshold was observed in patients with
risk factors (mainly hypertension and diabetes),
in comparison to 40 Gy in individuals without
such risk factors.66
In a retrospective series of 1109 patients treated
with 90Y-octreotide, 103 subjects (9.2%) experi-
enced grade 4 to 5 permanent renal toxicity.31
Multivariate regression revealed that the initial kid-
ney uptake was predictive for severe renal toxicity.
However, it seems likely that this relatively high
incidence of renal toxicity is related to the high
administered activities per cycle (3.7 GBq/m2
body surface, namely, activities of about 6.4 GBq
per cycle in a standard man) and to the fact that in-
dividuals with pre-existing impairment of renal
function were not excluded from PRRT. A further
consideration is that routine infusion of protective
amino acids was not used in the earlier component
of the study.65 From a hematological point of view,
PRRT is generally well tolerated. Severe, WHO
grade 3 or 4, toxicity occurs in less than 13% afterctreotate
177Lu-octreotate
(Gy) Mean (Gy/GBq) 29-GBq Course (Gy)
0.3–1.7 9–48
0.01–0.08 0.3–2.3
0.6–56 17–1624
ard full courses of therapy, using either 13 GBq or 29 GBq).
one marrow) are variable on an individual basis. Specific
centration in individual lesions and increase with radioac-
lso highly variable based on factors intrinsic to the tumor,
or cell membranes, the dimension of the lesions, and the
ection with amino acid solutions.
PRRT for Advanced Neuroendocrine Tumors 1390Y-octreotide and 10% after 177Lu-octreotate.
Nevertheless, sporadic cases of myelodysplastic
syndrome (MDS) or even overt acute leukemia
have been reported.14,38 Although predicted ab-
sorbed doses are lower than the conventional
threshold for harm, both acute and permanent
bone marrow toxicity is a cause for concern,
particularly with repeated isotope administra-
tions.14,24,29,34 Dose-finding phase I studies indi-
cate that the maximum cumulative administrable
activity per cycle of 90Y-octreotide, with renal pro-
tection, is 5.18 GBq.28 An additional important
observation derived from dosimetric studies is
that hyperfractionation can lower the renal and
bone marrow dose.58,66 No dose finding studies
have been conducted for 177Lu-octreotate. Inves-
tigations using the dose-limiting toxicity method
were abandoned, because literature data indi-
cated that 7.4 GBq could be safely used as a
maximum activity per cycle. Similarly, dosimetric
studies indicated the advantage of hyperfractiona-
tion in lowering the renal and bone marrow
dose.34,44,58,66 In a phase I–II study treated with
escalating activities of 177Lu-octreotate up to 7.4
GBq/cycle in 51 patients, no major acute or
delayed renal or hematological toxicity was
observed and cumulative renal and bone marrow
absorbed doses were within designated safety
limits.34 177Lu-octreotate demonstrated a higher
tolerability compared with 90Y-octreotide, largely
due to the physical characteristics of the 2
radioisotopes.
An additional, although rare, consideration
related to symptom exacerbation should be noted.
A minority of individuals with functional lesionsFig. 7. Utility and limitations of PRRT in the treatment of(eg, carcinoid, insulinoma, or Zollinger-Ellison syn-
drome) is susceptible. Paroxysmal amplification of
symptoms is a consequence of massive radiation-
induced cell lysis and subsequent release of
bioactive amines or peptides into the bloodstream
after PRRT. Such rare events can be rapidly
managed by administration of cold somatostatin
analogues, b-blockers, dextrose, or proton pump
inhibitor agents dependent on the specific
syndrome.67,68FINAL CONSIDERATIONS
PRRTwitheither 90Y-octreotideor 177Lu-octreotate
hasbeendemonstrated tobeefficient and relatively
safe provided the known thresholds of absorbed
and BED are carefully observed (Fig. 7). The renal
and hematological toxicity profile is acceptable
and canbe further defined, if appropriate protective
measures (such as amino acid protection and
activity fractionation) are undertaken.
PRRT has also been demonstrated to induce a
significant improvement in the QoL and diminution
of symptoms related to the disease in most treated
individuals. PRRT has a median PFS of more than
30 months, which represents a substantial
improvement in comparison with many other
therapeutic strategies used in NETs. In particular,
individuals responsive to PRRT with tumor stabili-
zation or reduction (w75% of the treated popula-
tion) demonstrate a significant increase in
survival (40–72 months from diagnosis). For these
reasons, despite the absence of the results of ran-
domized controlled trials, PRRT is considered one
of the fundamentally effective therapeuticNETs.
Bodei et al14strategies in the management of NETs. As such,
this modality of therapy (PRRT) has been included
in the therapeutic algorithms proposed for NET
disease management and has been accepted by
the pertinent medical and scientific soci-
eties.21,69–71 Despite such widespread accep-
tance and usage, there are several issues that
require clarification in the near future. In particular,
the precise timing of PRRT within the therapeutic
algorithm of NETs requires delineation and reflects
the relatively modest numbers of treated tumors,
the relatively short follow-up, and the absence of
randomized controlled trials. This critical limitation
in defining the precise utility of PRRT will be ad-
dressed, at least in small bowel NETs, based on
the outcome of a current ongoing multicenter
study.
A further requirement in demarcation of the effi-
cacy of PRRT is the need to more scientifically
assess theparametersof response to the treatment.
Inparticular, thespecificmolecular featuresof these
tumors (indicators of radiation sensitivity), prolifera-
tive markers (Ki-67), and molecular indices defining
response need delineation. Such informationwould
further amplify the ability to assess efficacy beyond
current parameters, such as evidence of disease
extension, basal isotope uptake at receptor imag-
ing, and morphologic assessment of the lesion
type. Thus, pretreatment functional analysis of tu-
mors using metabolomic parameters may convey
information in regard to the likelihood of radiation
sensitivity. Recent studies have noted that fluoro-
deoxyglucose (FDG) is a crucial parameter in pre-
dicting the duration of response to PRRT. Thus,
individuals with positive FDG exhibit a significantly
shorter PFS,72 clear evidence that tumor glucose
utilization represents a significant parameter in
predicting therapeutic efficacy.
A further consideration is the assessment of the
potential for renal and bone marrow toxicity. This
area has not been rigorously investigated at a sci-
entific level and remains a cause for concern
among clinicians, given the potential for an effec-
tive therapy to engender a potentially critical series
of adverse events. Radiation burden to tumor and
normal organs is difficult to establish with accept-
able accuracy, in the absence of the identification
of individual factors thatmight redefine susceptibil-
ity. Alternatively, the use of treatment schedules
with an excessively conservative approach, not
considering the individual dosimetry and other bio-
logic factors,may unreasonably limit the efficacy of
treatment (seeFig. 7). In this regard, the delineation
of molecular radiobiological parameters and indi-
vidual, genetically based features inherent to pre-
dicting the efficacy and safety of radiopeptide
therapy, would expedite the development ofpatient-specific and tumor-specific personalized
therapy. The establishment of a profile ofmolecular
determinants of both efficacy and toxicity would
facilitate the use of the most efficient tumor irradia-
tion and, at the same time, define the most conser-
vative safety profile with respect to normal organs.REFERENCES
1. Modlin IM, Oberg K, Chung DC, et al. Gastroenter-
opancreatic neuroendocrine tumours. Lancet
Oncol 2008;9:61–72.
2. Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN
Clinical Practice Guidelines in Oncology: neuroen-
docrine tumors. J Natl Compr Canc Netw 2009;7:
712–47.
3. Mallory GW, Fang S, Giannini C, et al. Brain carci-
noid metastases: outcomes and prognostic fac-
tors. J Neurosurg 2013;118:889–95. http://dx.doi.
org/10.3171/2013.1.JNS121556.
4. Frilling A, Modlin I, Kidd M, et al. Recommenda-
tions for management of patients with neuroendo-
crine liver metastases. Lancet Oncol 2014;15(1):
e8–21.
5. Saxena A, Chua TC, Sarkar A, et al. Progression
and survival results after radical hepatic metasta-
sectomy of indolent advanced neuroendocrine
neoplasms (NENs) supports an aggressive surgi-
cal approach. Surgery 2011;149:209–20.
6. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prog-
nostic factors of long-term outcome in gastroenter-
opancreatic neuroendocrine tumours. Endocr Relat
Cancer 2008;15:1083–97.
7. McDermott EW, Guduric B, Brennan MF. Prog-
nostic variables in patients with gastrointestinal
carcinoid tumours. Br J Surg 1994;81:1007–9.
8. Rindi G, D’Adda T, Froio E, et al. Prognostic factors
in gastrointestinal endocrine tumors. Endocr Pathol
2007;18:145–9.
9. Pavel M, Baudin E, Couvelard A, et al. ENETS
Consensus Guidelines for the management of pa-
tients with liver and other distant metastases from
neuroendocrine neoplasms of foregut, midgut,
hindgut, and unknown primary. Neuroendocri-
nology 2012;95:157–76.
10. Modlin IM, Moss SF, Chung DC, et al. Priorities for
improving the management of gastroenteropancre-
atic neuroendocrine tumors. J Natl Cancer Inst
2008;100:1282–9.
11. Weber HC. Medical treatment of neuroendocrine
tumours. Curr Opin Endocrinol Diabetes Obes
2013;20:27–31. http://dx.doi.org/10.1097/MED.
1090b1013e32835c32034f.
12. Doherty G. Surgical treatment of neuroendocrine
tumors (including carcinoid). Curr Opin Endocrinol
Diabetes Obes 2013;20:32–6. http://dx.doi.org/10.
1097/MED.1090b1013e32835b32837efa.
PRRT for Advanced Neuroendocrine Tumors 1513. Stevenson R, Libutti SK, Saif MW. Novel agents in
gastroenteropancreatic neuroendocrine tumors.
JOP 2013;14:152–4. http://dx.doi.org/10.6092/1590-
8577/1470.
14. Kwekkeboom DJ, Mueller-Brand J, Paganelli G,
et al. Overview of results of peptide receptor radio-
nuclide therapy with 3 radiolabeled somatostatin
analogs. J Nucl Med 2005;46(Suppl 1):62S–6S.
15. Turner NC, Strauss SJ, Sarker D, et al. Chemo-
therapy with 5-fluorouracil, cisplatin and streptozo-
cin for neuroendocrine tumours. Br J Cancer 2010;
102:1106–12.
16. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for
the management of gastroenteropancreatic neuro-
endocrine (including carcinoid) tumours (NETs).
Gut 2012;61:6–32.
17. Reubi JC, Scha¨r JC, Waser B, et al. Affinity profiles
for human somatostatin receptor subtypes SST1-
SST5 of somatostatin radiotracers selected for
scintigraphic and radiotherapeutic use. Eur J
Nucl Med 2000;27:273–82.
18. Hofland LJ, Lamberts SW. The pathophysiological
consequences of somatostatin receptor internali-
zation and resistance. Endocr Rev 2003;24:28–47.
19. Rinke A, Mu¨ller HH, Schade-Brittinger C, et al,
PROMID Study Group. Placebo-controlled,
double-blind, prospective, randomized study on
the effect of octreotide LAR in the control of tumor
growth in patients with metastatic neuroendocrine
midgut tumors: a report from the PROMID Study
Group. J Clin Oncol 2009;27:4656–63.
20. Caplin M, Ruszniewski P, Pavel M, et al. A random-
ized, double-blind, placebo-Controlled study of
Lanreotide Antiproliferative Response in patients
with gastroenteropancreatic NeuroEndocrine Tu-
mors (CLARINET) - European Cancer Congress
2013 (ECCO-ESMO-ESTRO). Amsterdam, Nether-
lands, September 27 – October 01, 2013.
21. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint
IAEA, EANM, and SNMMI practical guidance on
peptide receptor radionuclide therapy (PRRNT) in
neuroendocrine tumours. Eur J Nucl Med Mol Im-
aging 2013;40:800–16.
22. Reubi J. Peptide receptor expression in GEP-NET.
Virchows Arch 2007;451(Suppl 1):S47–50.
23. Krenning EP, Kooij PP, Bakker WH, et al. Radio-
therapy with a radiolabeled somatostatin analogue,
[111In-DTPA-D-Phe1]-octreotide. A case history.
Ann N Y Acad Sci 1994;15:496–506.
24. Valkema R, De Jong M, Bakker WH, et al. Phase I
study of peptide receptor radionuclide therapy
with [In-DTPA]-octreotide: the Rotterdam experi-
ence. Semin Nucl Med 2002;32:110–22.
25. Heppeler A, Froidevaux S, Ma¨cke HR, et al. Radio-
metal-labelled macrocyclic chelator–derivatised
somatostatin analogue with superb tumour-
targeting properties and potential for receptor–mediated internal radiotherapy. Chem Eur 1999;7:
1974–81.
26. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-
90 and indium-111 labelling, receptor binding and
biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide,
a promising somatostatin analogue for radionu-
clide therapy. Eur J Nucl Med 1997;24:368–71.
27. Otte A, Mu¨ller-Brand J, Dellas S, et al. Yttrium-90-
labelled somatostatin-analogue for cancer treat-
ment. Lancet 1998;7(351):417–8.
28. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-
mediated radionuclide therapy with 90Y-DOTATOC
in association with amino acid infusion: a phase I
study. Eur J Nucl Med Mol Imaging 2003;30:
207–16.
29. Bodei L, Cremonesi M, Grana C, et al. Receptor
radionuclide therapy with 90Y-[DOTA]0-Tyr3-oc-
treotide (90Y-DOTATOC) in neuroendocrine tu-
mours. Eur J Nucl Med Mol Imaging 2004;31:
1038–46.
30. Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, et al.
90Y-edotreotide for metastatic carcinoid refractory
to octreotide. J Clin Oncol 2010;28:1652–9.
31. Imhof A, Brunner P, Marincek N, et al. Response,
survival, and long-term toxicity after therapy with
the radiolabeled somatostatin analogue [90Y-
DOTA]-TOC in metastasized neuroendocrine can-
cers. J Clin Oncol 2011;29:2416–23.
32. Kwekkeboom DJ, Bakker WH, Kooij PP, et al.
[177Lu-DOTA0Tyr3]octreotate: comparison with
[111In-DTPA0]octreotide in patients. Eur J Nucl
Med 2001;28:1319–25.
33. Kwekkeboom DJ, de Herder WW, Kam BL, et al.
Treatment with the radiolabeled somatostatin
analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, ef-
ficacy, and survival. J Clin Oncol 2008;26:2124–30.
34. Bodei L, Cremonesi M, Grana CM, et al. Peptide re-
ceptor radionuclide therapy with (1)(7)(7)Lu-DOTA-
TATE: the IEO phase I-II study. Eur J Nucl Med Mol
Imaging 2011;38:2125–35.
35. Bodei L, FeroneD,GranaCM,et al. Peptide receptor
therapies in neuroendocrine tumors. J Endocrinol
Invest 2009;32:360–9.
36. Mizutani G, Nakanishi Y, Watanabe N, et al. Expres-
sion of Somatostatin Receptor (SSTR) subtypes
(SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors
using real-time RT-PCR method and immunohisto-
chemistry. Acta Histochem Cytochem 2012;45:
167–76. http://dx.doi.org/10.1267/ahc.12006.
37. Dale R, Carabe-Fernandez A. The radiobiology of
conventional radiotherapy and its application to
radionuclide therapy. Cancer Biother Radiopharm
2005;20:47–51.
38. Kwekkeboom DJ, Kam BL, van Essen M, et al. So-
matostatin-receptor-based imaging and therapy of
gastroenteropancreatic neuroendocrine tumors.
Endocr Relat Cancer 2010;17:R53–73.
Bodei et al1639. Cwikla JB, Sankowski A, Seklecka N, et al. Effi-
cacy of radionuclide treatment DOTATATE Y-90
in patients with progressive metastatic gastroen-
teropancreatic neuroendocrine carcinomas (GEP-
NETs): a phase II study. Ann Oncol 2010;21:
787–94.
40. Pfeifer AK, Gregersen T, Gronbaek H, et al. Peptide
receptor radionuclide therapy with Y-DOTATOC and
(177)Lu-DOTATOC in advanced neuroendocrine tu-
mors: results from a Danish cohort treated in
Switzerland. Neuroendocrinology 2011;93:189–96.
http://dx.doi.org/10.1159/000324096.
41. Paganelli G, Zoboli S, Cremonesi M, et al. Recep-
tor-mediated radiotherapy with 90Y-DOTA-D-
Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:
426–34.
42. Valkema R, Pauwels S, Kvols LK, et al. Survival and
response after peptide receptor radionuclide ther-
apy with [90Y-DOTA0,Tyr3]octreotide in patients
with advanced gastroenteropancreatic neuroendo-
crine tumors. Semin Nucl Med 2006;36:147–56.
43. Yachida S, Vakiani E, White CM, et al. Small cell
and large cell neuroendocrine carcinomas of the
pancreas are genetically similar and distinct from
well-differentiated pancreatic neuroendocrine tu-
mors. Am J Surg Pathol 2012;36:173–84. http://
dx.doi.org/10.1097/PAS.0b013e3182417d36.
44. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al.
Radiolabeled somatostatin analog [177Lu-
DOTA0,Tyr3]octreotate in patients with endocrine
gastroenteropancreatic tumors. J Clin Oncol
2005;23:2754–62.
45. Waldherr C, Pless M, Maecke HR, et al. Tumor
response and clinical benefit in neuroendocrine tu-
mors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med
2002;43:610–6.
46. De Jong M, Valkema R, Jamar F, et al. Somatostatin
receptor-targeted radionuclide therapy of tumors:
preclinical and clinical findings. Semin Nucl Med
2002;32:133–40.
47. de Jong M, Breeman WA, Valkema R, et al. Combi-
nation radionuclide therapy using 177Lu- and 90Y-
labeled somatostatin analogs. J Nucl Med 2005;
46(Suppl 1):13S–7S.
48. Kunikowska J, Kro´licki L, Hubalewska-
Dydejczyk A, et al. Clinical results of radionuclide
therapy of neuroendocrine tumours with (90)Y-DO-
TATATE and tandem (90)Y/(177)Lu-DOTATATE:
which is a better therapy option? Eur J Nucl Med
Mol Imaging 2011;38:1788–97.
49. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treat-
ment of patients with gastro-entero-pancreatic
(GEP) tumours with the novel radiolabelled somato-
statin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Eur J Nucl Med Mol Imaging 2003;30:417–22.
50. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Qual-
ity of life in patients with gastroenteropancreatictumors treated with [177Lu-DOTA0,Tyr3]octreotate.
J Clin Oncol 2004;22:2724–9.
51. Khan S, Krenning EP, van Essen M, et al. Quality of
life in 265 patients with gastroenteropancreatic or
bronchial neuroendocrine tumors treated with
[177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2011;
52:1361–8.
52. Sansovini M, Severi S, Ambrosetti A, et al. Treat-
ment with the radiolabelled somatostatin analog
Lu-DOTATATE for advanced pancreatic neuroen-
docrine tumors. Neuroendocrinology 2013;97:
347–54.
53. van Essen M, Krenning EP, Bakker WH, et al. Pep-
tide receptor radionuclide therapy with 177Lu-oc-
treotate in patients with foregut carcinoid tumours
of bronchial, gastric and thymic origin. Eur J Nucl
Med Mol Imaging 2007;34:1219–27.
54. van Essen M, Krenning EP, Kam BL, et al. Salvage
therapy with (177)Lu-octreotate in patients with
bronchial and gastroenteropancreatic neuroendo-
crine tumors. J Nucl Med 2010;51:383–90.
55. van Essen M, Krenning EP, Kam BL, et al. Report
on short-term side effects of treatments with
177Lu-octreotate in combination with capecitabine
in seven patients with gastroenteropancreatic
neuroendocrine tumours. Eur J Nucl Med Mol Im-
aging 2008;35:743–8.
56. Claringbold PG, Brayshaw PA, Price RA, et al.
Phase II study of radiopeptide 177Lu-octreotate
and capecitabine therapy of progressive dissemi-
nated neuroendocrine tumours. Eur J Nucl Med
Mol Imaging 2011;38:302–11.
57. Waldherr C, Pless M, Maecke HR, et al. The clinical
value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-
DOTATOC) in the treatment of neuroendocrine tu-
mours: a clinical phase II study. Ann Oncol 2001;
120:941–5.
58. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for
treatment with radiolabelled somatostatin ana-
logues. A review. Q J Nucl Med Mol Imaging
2010;54:37–51.
59. Cassady JR. Clinical radiation nephropathy. Int J
Radiat Oncol Biol Phys 1995;31:1249–56.
60. Daly R. Use of the linear-quadratic radiobiological
model for quantifying kidney response in targeted
radiotherapy. Cancer Biother Radiopharm 2004;
19:363–70.
61. Barone R, Borson-Chazot F, Valkema R, et al. Pa-
tient-specific dosimetry in predicting renal toxicity
with (90)Y-DOTATOC: relevance of kidney volume
and dose rate in finding a dose-effect relationship.
J Nucl Med 2005;46(Suppl 1):99S–106S.
62. de Jong M, Krenning E. New advances in peptide
receptor radionuclide therapy. J Nucl Med 2002;
43:617–20.
63. Bernard BF, Krenning EP, Breeman WA, et al.
D-lysine reduction of indium-111 octreotide and
PRRT for Advanced Neuroendocrine Tumors 17yttrium-90 octreotide renal uptake. J Nucl Med
1997;38:1929–33.
64. Valkema R, Pauwels SA, Kvols LK, et al. Long-term
follow-up of renal function after peptide receptor
radiation therapy with (90)Y-DOTA(0),Tyr(3)-
octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
J Nucl Med 2005;46(Suppl 1):83S–91S.
65. Cybulla M, Weiner SM, Otte A. End-stage renal dis-
ease after treatment with 90Y-DOTATOC. Eur J
Nucl Med 2001;28:1552–4.
66. Bodei L, Cremonesi M, Ferrari M, et al. Long-term
evaluation of renal toxicity after peptide receptor
radionuclide therapy with 90Y-DOTATOC and
177Lu-DOTATATE: the role of associated risk fac-
tors. Eur J Nucl Med Mol Imaging 2008;35:
1847–56.
67. Davı` MV, Bodei L, Francia G, et al. Carcinoid crisis
induced by receptor radionuclide therapy with 90Y-
DOTATOC in a case of liver metastases from bron-
chial neuroendocrine tumor (atypical carcinoid).
J Endocrinol Invest 2006;29:563–7.
68. de Keizer B, van Aken MO, Feelders RA, et al. Hor-
monal crises following receptor radionuclidetherapy with the radiolabeled somatostatin
analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J
Nucl Med Mol Imaging 2008;35:749–55.
69. O¨berg K, Knigge U, Kwekkeboom D, et al, ESMO
Guidelines Working Group. Neuroendocrine
gastro-entero-pancreatic tumors: ESMO Clinical
Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2012;23(Suppl 7):vii124–30.
70. O¨berg K, Hellman P, Ferolla P, et al, ESMO Guide-
lines Working Group. Neuroendocrine bronchial
and thymic tumors: ESMO Clinical Practice Guide-
lines for diagnosis, treatment and follow-up. Ann
Oncol 2012;23(Suppl 7):vii120–3.
71. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al.
ENETS Consensus Guidelines for the Standards of
Care in Neuroendocrine Tumors: peptide receptor
radionuclide therapywith radiolabeled somatostatin
analogs. Neuroendocrinology 2009;90:220–6.
72. Severi S, Nanni O, Bodei L, et al. Role of 18FDG
PET/CT in patients treated with 177Lu-DOTATATE
for advanced differentiated neuroendocrine tu-
mours. Eur J Nucl Med Mol Imaging 2013;40:
881–8.
